Envoy Medical, INC 8-K filings

Envoy Medical announced Q2 2026 financial results, highlighting the submission of the first module of its Acclaim cochlear implant PMA application to the FDA and positive 12-month clinical trial data.

Envoy Medical, Inc. has terminated its At-The-Market (ATM) equity offering agreement, previously allowing for up to $15 million in stock sales, citing confidence in its current capital position.

Envoy Medical, Inc. announced updated compensation terms and significant equity grants for CEO Brent Lucas tied to strategic performance and FDA approval milestones.

Envoy Medical has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, potentially involving a reverse stock split.

Envoy Medical's stockholders approved amendments to the Equity Incentive Plan and Employee Stock Purchase Plan, increasing share availability.

Envoy Medical announced the completion of its pivotal clinical trial enrollment for the Acclaim cochlear implant and a significant capital raise, advancing its path toward FDA approval.

Envoy Medical, Inc. has expanded its Board of Directors to seven members with the appointment of industry veteran Charles S. McKhann.

Envoy Medical, Inc. has dismissed Grant Thornton LLP and appointed EisnerAmper LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.

Envoy Medical announced full year 2025 financial results, highlighted by FDA approval for its Acclaim Cochlear Implant trial expansion, significant debt reduction, and a transformational capital raise.

Envoy Medical Inc. announced it has regained compliance with Nasdaq's minimum Market Value of Listed Securities requirement, ensuring its continued listing.

Envoy Medical Inc. closed an upsized public offering raising $30.0 million upfront, with potential for an additional $48.0 million from milestone-linked warrants, extending its cash runway into late 2027.

Envoy Medical, Inc. announced the grant of stock options to its CEO, Brent Lucas, and Interim CFO, Robert Potashnick, under its 2023 Equity Incentive Plan.

Envoy Medical, Inc. has extended the expiration date of 1.13 million outstanding Shortfall Warrants held by Meteora Parties from December 31, 2025, to December 31, 2026.

Envoy Medical, Inc. highlights late-stage development of its Acclaim CI, a first-of-its-kind fully-implanted cochlear implant, targeting an $84 billion U.S. market.

Envoy Medical, Inc. stockholders approved the issuance of warrants and underlying Class A Common Stock to comply with Nasdaq listing rules at a Special Meeting held on November 26, 2025.

Envoy Medical, Inc. received a Nasdaq staff determination notice for failing to meet the $1.00 minimum bid price requirement, initiating a 180-day compliance period.

Envoy Medical reports a transformational third quarter, eliminating $32 million in debt, strengthening its balance sheet, and advancing its pivotal Acclaim cochlear implant clinical trial with FDA approval for the final stage.

Envoy Medical, Inc. has been granted an exception by the Nasdaq Hearings Panel to maintain its listing until February 23, 2026, despite not meeting the $35 million market value requirement.

Envoy Medical Inc. announced a registered direct offering of common stock and a concurrent private placement of warrants, raising $4 million upfront with a potential for an additional $12 million.

Envoy Medical received FDA approval to advance its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage, based on promising three-month data.

Envoy Medical Inc. announced a registered direct offering of common stock and a concurrent private placement of warrants, aiming to raise up to $10 million for working capital.

Envoy Medical Inc. announced the grant of a new European patent for its advanced fully implanted cochlear system, strengthening its global intellectual property portfolio.

Envoy Medical, Inc. entered into a Voting and Warrant Extension Agreement with major shareholder Glen A. Taylor, securing voting support for Nasdaq compliance and extending 3.5 million warrants until December 31, 2028.

Envoy Medical, Inc. received a Nasdaq determination letter for failing to regain compliance with the minimum market value requirement and has requested a hearing to appeal the decision.

Envoy Medical, Inc. has extinguished over $32 million in promissory note obligations for a one-time payment of $100,000, significantly strengthening its balance sheet, as its largest stockholder Glen Taylor resigns from the board.

Envoy Medical reported its second quarter 2025 financial results, highlighting significant progress in its Acclaim cochlear implant clinical trial and the approval of new CPT codes for its Esteem device, despite an increase in net losses and a growing accumulated deficit.

Envoy Medical, Inc. has amended the exercise price of over 3.2 million outstanding Shortfall Warrants, linking it to a weekly volume-weighted average price with a minimum of $1.50 per share.

Envoy Medical, Inc. has drawn the remaining $5 million from a promissory note with GAT Funding, LLC, an entity controlled by its board member and controlling stockholder, and issued warrants for 750,000 shares as a commitment fee.

Envoy Medical, Inc. has announced the appointment of Robert Potashnick as its Interim Chief Financial Officer, effective June 23, 2025, engaged on a fractional consulting basis.

Envoy Medical, Inc. announced that its stockholders approved an amendment to the 2023 Equity Incentive Plan, making 1.5 million previously restricted shares available for issuance, and re-elected two Class II directors at its 2025 Annual Meeting.